Immunoglobulin A nephropathy (IgAN) is a progressive glomerular disease and a leading cause of chronic kidney disease (CKD), with up to 40% of patients advancing to kidney failure within two decades. Despite guideline-recommended management emphasizing supportive care and RAAS inhibition, many patients continue to experience persistent proteinuria and declining renal function. Clinical practice remains inconsistent, particularly regarding the use of assessment tools and initiation of immunosuppressive therapies. While updated risk scoring models, AI-driven risk stratification tools, and biomarker-guided assessments have emerged, awareness and utilization in routine care are limited. As new therapies enter practice, clinicians require practical education to incorporate evolving evidence into patient care. To meet this need, a virtual journal club series will deliver concise, case-based learning that translates recent clinical trial findings into actionable strategies. This format is designed to foster reflection, support informed decision-making, and help nephrologists and other HCPs optimize treatment pathways for patients living with IgAN.
In this CMEO Journal Club, expert faculty will present and discuss the very latest research abstracts from the American Academy of Neurology (AAN) 2025 Annual Meeting and the Associated Professional Sleep Societies (APSS) SLEEP 2025 Annual Meeting, including the latest information on psychiatric and CV/CM comorbidities for patients living with IH and narcolepsy, the impact of these comorbidities on patients’ QoL, and how to customize treatment that mitigates risk.
In this CME Outfitters Journal Club, expert faculty will present and discuss the very latest research on international diagnostic and treatment guidelines as well as clinical trial data from published abstracts on the latest treatment options for CIDP.
In this CME Outfitters Journal Club, expert faculty will present and discuss the very latest research abstracts from the 2024 Peripheral Nerve Society Annual Meeting (June 2024), including the latest research on the role of the complement system in CIPD, clinical and electrophysical variants of CIDP, and standard vs. emerging treatment options for CIDP.
In this second installment of a two-part Journal Club series, An Expanded View of Alzheimer’s Disease Neuropathology: Translation to the Early Identification of Disease, expert faculty will evaluate the latest data from ATT clinical trials and discuss strategies for identifying appropriate patients based on both pathological and clinical characteristics to ensure timely and optimal management of patients with early symptomatic AD.
In this first installment of a two-part Journal Club series, An Expanded View of Alzheimer’s Disease Neuropathology: Translation to the Early Identification of Disease, expert faculty will present the latest information on the neuropathological changes associated with AD, their relevance to the cognitive and functional decline of early AD, as well as the role of phosphorylated tau biomarkers as early indicators of both amyloid and tau accumulation.